Profile data is unavailable for this security.
About the company
Sun Pharma Advanced Research Company Limited is an India-based clinical-stage biopharmaceutical company that focuses on developing therapeutics to improve standards of care for patients worldwide. The Company’s therapeutic focus is in the area of oncology, neurology and immunology. Its lead oncology programs include vodobatinib (SCO-088), a BCR-ABL targeting tyrosine kinase inhibitor for refractory chronic myelogenous leukemia, and an anti-MUC-1 antibody-drug conjugate (ADC) with the potential to treat multiple cancers. The Company’s other programs include Sezaby for the treatment of neonatal seizures, Vodobatinib for the treatment of neurodegenerative disorders (SCC-138), Vibozilimod for the treatment of autoimmune disorders (SCD-044), SCD-153 for the treatment of alopecia areata, SBO-154 for multiple cancer indications and SCO-155 for treatment of cancer. SBO-154 is an anti MUC1 ADC being developed for multiple tumor types expressing MUC1.
- Revenue in INR (TTM)531.36m
- Net income in INR-2.68bn
- Incorporated2006
- Employees316.00
- LocationSun Pharma Advanced Research Co Ltd17B Mahal Industrial EstateMahakali Caves Road, Andheri (East)MUMBAI 400093IndiaIND
- Phone+91 2 266455645
- Fax+91 2 266455685
- Websitehttps://www.sparc.life/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hikal Ltd | 16.99bn | 101.00m | 23.51bn | 2.06k | 232.08 | 1.97 | 14.55 | 1.38 | 0.8216 | 0.8216 | 137.81 | 96.86 | 0.7065 | 2.01 | 4.59 | 8,239,573.00 | 0.42 | 4.78 | 0.6016 | 7.00 | 55.49 | 48.00 | 0.5945 | 5.71 | 0.5418 | 1.11 | 0.3639 | 14.83 | 4.21 | 4.29 | 30.46 | 1.46 | -2.77 | 3.13 |
| Unichem Laboratories Ltd | 22.14bn | 2.95bn | 26.98bn | 3.33k | 9.17 | -- | 6.44 | 1.22 | 41.79 | 41.79 | 314.32 | -- | -- | -- | -- | 6,654,374.00 | -- | -0.5598 | -- | -0.6977 | 54.06 | 55.09 | 13.32 | -1.18 | -- | 3.47 | -- | -- | 18.25 | 13.85 | 246.67 | -- | -18.68 | -- |
| SMS Pharmaceuticals Ltd | 8.97bn | 895.91m | 29.87bn | 1.47k | 31.49 | -- | 23.79 | 3.33 | 10.13 | 10.13 | 101.51 | -- | -- | -- | -- | 6,102,851.00 | -- | 5.58 | -- | 7.66 | 32.55 | 33.78 | 9.71 | 8.05 | -- | 5.85 | -- | 5.72 | 10.36 | 13.70 | 38.75 | 16.97 | 23.62 | 9.86 |
| Gufic BioSciences Ltd | 8.74bn | 569.19m | 31.54bn | 1.99k | 55.39 | 5.00 | 37.16 | 3.61 | 5.68 | 5.68 | 87.10 | 62.94 | 0.7354 | 1.87 | 2.75 | 4,394,322.00 | 4.79 | 10.27 | 7.34 | 16.11 | 55.47 | 46.41 | 6.52 | 10.48 | 1.06 | 3.13 | 0.3691 | 1.31 | 1.63 | 16.69 | -19.14 | 25.15 | 13.64 | 14.87 |
| Dishman Carbogen Amcis Ltd | 27.97bn | 1.19bn | 32.86bn | 1.11k | 27.67 | -- | 7.34 | 1.17 | 7.57 | 7.57 | 178.50 | -- | -- | -- | -- | 25,287,880.00 | -- | -0.7247 | -- | -0.9005 | 84.96 | 74.27 | 4.25 | -2.77 | -- | 1.31 | -- | -- | 3.66 | 5.82 | 102.11 | -54.07 | -11.91 | -- |
| RPG Life Sciences Ltd | 6.74bn | 2.03bn | 33.69bn | 1.33k | 16.63 | -- | 15.06 | 5.00 | 122.51 | 122.51 | 407.37 | -- | -- | -- | -- | 5,061,758.00 | -- | 21.05 | -- | 27.78 | 64.34 | 63.28 | 30.07 | 16.68 | -- | 174.47 | -- | 24.92 | 12.26 | 11.71 | 109.03 | 44.58 | 27.39 | 37.97 |
| Aarti Drugs Ltd | 25.22bn | 2.03bn | 34.25bn | 1.28k | 17.00 | -- | 12.86 | 1.36 | 22.07 | 22.07 | 274.99 | -- | -- | -- | -- | 19,639,960.00 | -- | 9.09 | -- | 14.39 | 36.35 | 22.09 | 8.03 | 8.08 | -- | 7.00 | -- | 6.07 | -5.60 | 5.74 | -1.90 | 3.53 | 29.85 | 14.87 |
| Orchid Pharma Ltd | 8.21bn | 522.57m | 34.99bn | 737.00 | 66.92 | 2.75 | 40.22 | 4.26 | 10.31 | 10.31 | 162.05 | 251.16 | 0.4893 | 1.58 | 3.94 | 11,143,480.00 | 3.10 | 1.40 | 3.63 | 1.72 | 39.83 | 35.89 | 6.33 | 2.75 | 1.90 | 2.18 | 0.181 | -- | 12.48 | 13.76 | 8.13 | -- | 104.06 | -- |
| Gujarat Themis Biosyn Ltd | 1.59bn | 477.88m | 36.00bn | 221.00 | 75.32 | -- | 62.18 | 22.59 | 4.39 | 4.39 | 14.62 | -- | -- | -- | -- | 7,209,322.00 | -- | 30.70 | -- | 34.37 | 62.78 | 68.03 | 29.99 | 35.51 | -- | 55.73 | -- | -- | -11.20 | 12.12 | -17.56 | 15.55 | 104.61 | 24.95 |
| Senores Pharmaceuticals Ltd | 5.89bn | 1.02bn | 37.66bn | 194.00 | 36.49 | -- | 28.96 | 6.40 | 22.41 | 22.41 | 130.31 | -- | -- | -- | -- | 30,336,080.00 | -- | -- | -- | -- | 58.73 | -- | 17.48 | -- | -- | 5.94 | -- | -- | 85.64 | -- | 86.17 | -- | -- | -- |
| Innova Captab Ltd | 14.97bn | 1.32bn | 40.36bn | 1.95k | 30.49 | -- | 22.93 | 2.70 | 23.13 | 23.13 | 261.52 | -- | -- | -- | -- | 7,676,703.00 | -- | 10.02 | -- | 15.00 | 36.26 | 27.20 | 8.85 | 8.72 | -- | 12.45 | -- | -- | 15.02 | 27.21 | 35.95 | 35.69 | 109.94 | -- |
| Sun Pharma Advanced Research Co Ltd | 531.36m | -2.68bn | 44.45bn | 316.00 | -- | -- | -- | 83.65 | -8.26 | -8.26 | 1.64 | -- | -- | -- | -- | 1,681,519.00 | -- | -60.53 | -- | -129.98 | 54.57 | 77.17 | -504.20 | -168.34 | -- | -8.82 | -- | -- | -5.00 | -1.35 | 11.55 | -- | -28.16 | -- |
| Zota Health Care Ltd | 4.73bn | -726.58m | 48.48bn | 519.00 | -- | -- | -- | 10.25 | -23.98 | -23.98 | 157.24 | -- | -- | -- | -- | 9,108,992.00 | -- | -7.79 | -- | -10.57 | 57.22 | 42.02 | -15.34 | -8.01 | -- | -3.71 | -- | -- | 62.32 | 25.23 | -293.08 | -- | 49.40 | 0.00 |
| Supriya Lifescience Ltd | 7.35bn | 1.85bn | 57.15bn | 515.00 | 30.81 | -- | 27.05 | 7.77 | 23.05 | 23.05 | 91.47 | -- | -- | -- | -- | 14,280,700.00 | -- | 18.45 | -- | 21.63 | 72.33 | 59.62 | 25.19 | 25.45 | -- | 129.43 | -- | 3.59 | 22.11 | 17.45 | 57.80 | 20.69 | 45.94 | -- |
| F D C Ltd | 20.78bn | 2.17bn | 63.99bn | 6.86k | 29.53 | -- | 23.09 | 3.08 | 13.31 | 13.31 | 127.73 | -- | -- | -- | -- | 3,030,531.00 | -- | 11.35 | -- | 12.96 | 67.92 | 60.85 | 10.43 | 14.75 | -- | 47.92 | -- | 6.34 | 8.50 | 9.42 | -12.59 | 2.15 | 25.37 | -- |
| Shilpa Medicare Ltd | 14.32bn | 1.50bn | 64.84bn | 898.00 | 42.77 | -- | 24.20 | 4.53 | 7.75 | 7.75 | 73.87 | -- | -- | -- | -- | 15,945,910.00 | -- | 2.02 | -- | 2.61 | 70.47 | 60.07 | 10.48 | 5.17 | -- | 4.67 | -- | 9.89 | 11.71 | 7.22 | 145.63 | -12.90 | 16.09 | -- |
Data as of Feb 12 2026. Currency figures normalised to Sun Pharma Advanced Research Co Ltd's reporting currency: Indian Rupee INR
2.32%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 07 Jan 2026 | 3.86m | 1.19% |
| ICICI Prudential Asset Management Co. Ltd. (Invt Mgmt)as of 31 Dec 2025 | 2.13m | 0.66% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 615.45k | 0.19% |
| SSgA Funds Management, Inc.as of 08 Jan 2026 | 461.56k | 0.14% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Dec 2025 | 324.93k | 0.10% |
| Vanguard Fiduciary Trust Co.as of 30 Nov 2025 | 120.89k | 0.04% |
| Vanguard Asset Management Ltd.as of 31 Dec 2025 | 25.95k | 0.01% |
| Groww Asset Management Ltd.as of 31 Dec 2025 | 1.57k | 0.00% |
| Bandhan AMC Ltd.as of 31 Dec 2025 | 1.38k | 0.00% |
| Angel One Asset Management Co. Ltd.as of 31 Dec 2025 | 441.00 | 0.00% |
More ▼
Data from 30 Jun 2025 - 15 Jan 2026Source: FactSet Research Systems Inc.
